---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-040703"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-04-08T23:59:59+00:00"
generated_at: "2026-05-15T06:52:48.202141+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# iBio gets TGA/ethics approval for IBIO-600 Phase 1; warrants expire May 12

## Summary
- Received CTN acknowledgement from Australia's TGA and ethics committee approval to initiate first-in-human Phase 1 trial of IBIO-600.
- First participant dosing expected in second quarter 2026.
- IBIO-600 is a long-acting anti-myostatin monoclonal antibody designed to preserve lean mass in obesity, with potential for 2-4 doses per year.
- Series G warrants (outstanding ~27.9M shares) will expire on May 12, 2026 – 30 trading days after this public announcement.
- If all Series G warrants exercised, an additional ~27.9M common shares issued plus Series H warrants for same amount.

## SEC filing metadata
- accession: 0001104659-26-040703
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-04-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000110465926040703/0001104659-26-040703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000110465926040703/ibio-20260408x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-040703
- JSON: https://secwatch.observer/filing/0001104659-26-040703.json
- Plain text: https://secwatch.observer/filing/0001104659-26-040703.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.